These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21107022)

  • 1. Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.
    Figg WD; Figg WD
    Cancer Biol Ther; 2010 Dec; 10(12):1233-4. PubMed ID: 21107022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
    Paller CJ; Antonarakis ES
    Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
    Pal SK; Twardowski P; Sartor O
    Clin Interv Aging; 2010 Dec; 5():395-402. PubMed ID: 21152241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.
    McKeage K
    Drugs; 2012 Jul; 72(11):1559-77. PubMed ID: 22818017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
    Oudard S
    Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabazitaxel for the treatment of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sartor O
    Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
    Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
    J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
    Rosenberg JE; Ryan CJ; Weinberg VK; Smith DC; Hussain M; Beer TM; Ryan CW; Mathew P; Pagliaro LC; Harzstark AL; Sharib J; Small EJ
    J Clin Oncol; 2009 Jun; 27(17):2772-8. PubMed ID: 19349545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxetaxel: new indication. Prostate cancer: a few more weeks.
    Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
    Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
    Song P; Huang C; Wang Y
    Int J Surg; 2018 Aug; 56():133-140. PubMed ID: 29906643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
    Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubulin-targeted agents including docetaxel and cabazitaxel.
    Cheetham P; Petrylak DP
    Cancer J; 2013; 19(1):59-65. PubMed ID: 23337758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
    Lheureux S; Joly F
    Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
    Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):192-205. PubMed ID: 21577234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
    Sartor O; Michels RM; Massard C; de Bono JS
    Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.